Standard BioTools Q2 revenue $21.8M, net loss improves; sells SomaLogic to Illumina for up to $425M

STANDARD BIOTOOLS INC.

2025-Q2 EPS reported -$0.16 revenue$41,984,000

Q2 2025 continuing ops revenue $21.8M, down 3% YoY; net loss $17.7M vs $25.4M loss a year ago.
Consumables revenue up 18% YoY to $10.5M; instruments down 26% to $5.2M; services down 8% to $6.1M.
Adjusted EBITDA loss $16.1M vs $17.4M; targeting adjusted EBITDA breakeven in 2026.
Announced sale of SomaLogic to Illumina for up to $425M cash plus royalties; expected close H1 2026.
FY2025 revenue outlook: combined $165-175M; continuing ops $78-83M; cash $239.7M, expects ≥$550M post-close.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.